Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

Hideki Ijichi, Tomoharu Yoshizumi, Toru Ikegami, Yuji Soejima, Tetsuo Ikeda, Hirofumi Kawanaka, Hideaki Uchiyama, Yo Ichi Yamashita, Masaru Morita, Eiji Oki, Koshi Mimori, Keishi Sugimachi, Hiroshi Saeki, Masayuki Watanabe, Ken Shirabe, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalUnknown Journal
Volume104
Issue number10
Publication statusPublished - Oct 2013

Fingerprint

hepatitis
transplantation
Living Donors
Hepatitis B
Hepatitis B virus
Liver Transplantation
Hepatocellular Carcinoma
virus
Recurrence
End Stage Liver Disease
DNA
chemotherapy
Graft Survival
Virus Diseases
Hepatitis B Surface Antigens
Immunoglobulins
Liver Diseases
antigen
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation. / Ijichi, Hideki; Yoshizumi, Tomoharu; Ikegami, Toru; Soejima, Yuji; Ikeda, Tetsuo; Kawanaka, Hirofumi; Uchiyama, Hideaki; Yamashita, Yo Ichi; Morita, Masaru; Oki, Eiji; Mimori, Koshi; Sugimachi, Keishi; Saeki, Hiroshi; Watanabe, Masayuki; Shirabe, Ken; Maehara, Yoshihiko.

In: Unknown Journal, Vol. 104, No. 10, 10.2013, p. 376-382.

Research output: Contribution to journalArticle

Ijichi, H, Yoshizumi, T, Ikegami, T, Soejima, Y, Ikeda, T, Kawanaka, H, Uchiyama, H, Yamashita, YI, Morita, M, Oki, E, Mimori, K, Sugimachi, K, Saeki, H, Watanabe, M, Shirabe, K & Maehara, Y 2013, 'Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.', Unknown Journal, vol. 104, no. 10, pp. 376-382.
Ijichi, Hideki ; Yoshizumi, Tomoharu ; Ikegami, Toru ; Soejima, Yuji ; Ikeda, Tetsuo ; Kawanaka, Hirofumi ; Uchiyama, Hideaki ; Yamashita, Yo Ichi ; Morita, Masaru ; Oki, Eiji ; Mimori, Koshi ; Sugimachi, Keishi ; Saeki, Hiroshi ; Watanabe, Masayuki ; Shirabe, Ken ; Maehara, Yoshihiko. / Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation. In: Unknown Journal. 2013 ; Vol. 104, No. 10. pp. 376-382.
@article{e94a1bc254554a498e55d9c0372f553f,
title = "Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.",
abstract = "Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.",
author = "Hideki Ijichi and Tomoharu Yoshizumi and Toru Ikegami and Yuji Soejima and Tetsuo Ikeda and Hirofumi Kawanaka and Hideaki Uchiyama and Yamashita, {Yo Ichi} and Masaru Morita and Eiji Oki and Koshi Mimori and Keishi Sugimachi and Hiroshi Saeki and Masayuki Watanabe and Ken Shirabe and Yoshihiko Maehara",
year = "2013",
month = "10",
language = "English",
volume = "104",
pages = "376--382",
journal = "Quaternary International",
issn = "1040-6182",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

AU - Ijichi, Hideki

AU - Yoshizumi, Tomoharu

AU - Ikegami, Toru

AU - Soejima, Yuji

AU - Ikeda, Tetsuo

AU - Kawanaka, Hirofumi

AU - Uchiyama, Hideaki

AU - Yamashita, Yo Ichi

AU - Morita, Masaru

AU - Oki, Eiji

AU - Mimori, Koshi

AU - Sugimachi, Keishi

AU - Saeki, Hiroshi

AU - Watanabe, Masayuki

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

PY - 2013/10

Y1 - 2013/10

N2 - Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

AB - Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

UR - http://www.scopus.com/inward/record.url?scp=84897577066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897577066&partnerID=8YFLogxK

M3 - Article

C2 - 24511669

AN - SCOPUS:84897577066

VL - 104

SP - 376

EP - 382

JO - Quaternary International

JF - Quaternary International

SN - 1040-6182

IS - 10

ER -